{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:19Z","timestamp":1787003659491,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Indo-French Centre for the Promotion of Advanced Research, Ministry of Science and Technology, Govt of India","award":["6702-1"],"award-info":[{"award-number":["6702-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83178-w","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T07:09:46Z","timestamp":1743059386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Network based approach for drug target identification in early onset Parkinson\u2019s disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Ashmita","family":"Dey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrittika","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjwal","family":"Maulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghamitra","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"83178_CR1","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3233\/JPD-223380","volume":"12","author":"A Kolicheski","year":"2022","unstructured":"Kolicheski, A. et al. Early-onset Parkinson\u2019s disease: Creating the right environment for a genetic disorder. J. Parkinsons Dis. 12, 2353\u20132367 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"83178_CR2","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1007\/s10072-023-06826-5","volume":"44","author":"R Bovenzi","year":"2023","unstructured":"Bovenzi, R. et al. Shaping the course of early-onset Parkinson\u2019s disease: Insights from a longitudinal cohort. Neurol. Sci. 44, 3151\u20133159 (2023).","journal-title":"Neurol. Sci."},{"key":"83178_CR3","first-page":"1","volume":"13","author":"M Kano","year":"2022","unstructured":"Kano, M. et al. Case report: Early-onset Parkinson\u2019s disease with initial spastic paraparesis and hyperreflexia caused by compound heterozygous PRKN-gene exon 2 and 4 deletions. Front. Neurol. 13, 1\u20136 (2022).","journal-title":"Front. Neurol."},{"key":"83178_CR4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/jmg.2008.063917","volume":"46","author":"J Brooks","year":"2009","unstructured":"Brooks, J. et al. Parkin and PINK1 mutations in early-onset Parkinson\u2019s disease: Comprehensive screening in publicly available cases and control. J. Med. Genet. 46, 375\u2013381 (2009).","journal-title":"J. Med. Genet."},{"key":"83178_CR5","first-page":"1","volume":"14","author":"P Hua","year":"2022","unstructured":"Hua, P. et al. Genetic Analysis of Patients With Early-Onset Parkinson\u2019s Disease in Eastern China. Front. Aging Neurosci. 14, 1\u20139 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"83178_CR6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","volume":"20","author":"O Rascol","year":"2021","unstructured":"Rascol, O., Fabbri, M. & Poewe, W. Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders. Lancet Neurol. 20, 1048\u20131056 (2021).","journal-title":"Lancet Neurol."},{"key":"83178_CR7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.109942","volume":"102","author":"TC Napier","year":"2020","unstructured":"Napier, T. C., Kirby, A. & Persons, A. L. The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson\u2019s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 102, 109942 (2020).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"83178_CR8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/cancers12020523","volume":"12","author":"C Sogawa","year":"2020","unstructured":"Sogawa, C. et al. Antiparkinson drug benztropine suppresses tumor growth, circulating tumor cells, and metastasis by acting on slc6a3\/dat and reducing stat3. Cancers 12, 523 (2020).","journal-title":"Cancers"},{"key":"83178_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40801-015-0008-7","volume":"2","author":"A Bitner","year":"2015","unstructured":"Bitner, A., Zalewski, P., Klawe, J. J. & Newton, J. L. Drug interactions in Parkinson\u2019s disease: Safety of pharmacotherapy for arterial hypertension. Drugs-Real World Outcomes 2, 1\u201312 (2015).","journal-title":"Drugs-Real World Outcomes"},{"key":"83178_CR10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/mds.10589","volume":"18","author":"N B\u00e9langer","year":"2003","unstructured":"B\u00e9langer, N., Gr\u00e9goire, L., Tahar, A. H. & B\u00e9dard, P. J. Chronic treatment with small doses of cabergoline prevents DOPA-induced Dyskinesias in parkinsonian monkeys. Mov. Disord. Off. J. Mov. Disord. Soc. 18, 1436\u20131441 (2003).","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"83178_CR11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","volume":"12","author":"RA Hauser","year":"2013","unstructured":"Hauser, R. A. et al. Extended-release carbidopa-levodopa (ipx066) compared with immediate-release carbidopa-levodopa in patients with parkinson\u2019s disease and motor fluctuations: A phase 3 randomised, double-blind trial. Lancet Neurol. 12, 346\u2013356 (2013).","journal-title":"Lancet Neurol."},{"key":"83178_CR12","unstructured":"Kanehisaa, M. & Goto, S. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 28 (2000)."},{"key":"83178_CR13","doi-asserted-by":"crossref","unstructured":"Croft, D. et al. Reactome: A database of reactions, pathways and biological processes. Nucleic Acids Res. 39 (2011).","DOI":"10.1093\/nar\/gkq1018"},{"key":"83178_CR14","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1042\/BST20120133","volume":"40","author":"JM Taymans","year":"2012","unstructured":"Taymans, J. M. The GTPase function of LRRK2. Biochem. Soc. Trans. 40, 1063\u20131069 (2012).","journal-title":"Biochem. Soc. Trans."},{"key":"83178_CR15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.parkreldis.2015.09.007","volume":"22","author":"T Konno","year":"2016","unstructured":"Konno, T., Ross, O. A., Puschmann, A., Dickson, D. W. & Wszolek, Z. K. Autosomal dominant Parkinson\u2019s disease caused by SNCA duplications. Parkinson. Relat. Disord. 22, S1\u2013S6 (2016).","journal-title":"Parkinson. Relat. Disord."},{"key":"83178_CR16","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1097\/00001756-200008030-00020","volume":"11","author":"R Kr\u00fcger","year":"2000","unstructured":"Kr\u00fcger, R. et al. Genetic analysis of the $$\\alpha$$2-macroglobulin gene in early-and late-onset Parkinson\u2019s disease. NeuroReport 11, 2439\u20132442 (2000).","journal-title":"NeuroReport"},{"key":"83178_CR17","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/01.wnl.0000187075.81589.fd","volume":"65","author":"S Karamohamed","year":"2005","unstructured":"Karamohamed, S. et al. Bdnf genetic variants are associated with onset age of familial Parkinson disease: gGene PD study. Neurology 65, 1823\u20131825 (2005).","journal-title":"Neurology"},{"key":"83178_CR18","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/mds.26290","volume":"30","author":"CR Swanson","year":"2015","unstructured":"Swanson, C. R. et al. Plasma apolipoprotein a1 associates with age at onset and motor severity in early Parkinson\u2019s disease patients. Mov. Disord. 30, 1648\u20131656 (2015).","journal-title":"Mov. Disord."},{"key":"83178_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neulet.2018.08.024","volume":"686","author":"Y Chen","year":"2018","unstructured":"Chen, Y. et al. The relationship between four GWAS-identified loci in Alzheimer\u2019s disease and the risk of Parkinson\u2019s disease, amyotrophic lateral sclerosis, and multiple system atrophy. Neurosci. Lett. 686, 205\u2013210 (2018).","journal-title":"Neurosci. Lett."},{"key":"83178_CR20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11064-008-9656-2","volume":"34","author":"RL Miller","year":"2009","unstructured":"Miller, R. L., James-Kracke, M., Sun, G. Y. & Sun, A. Y. Oxidative and inflammatory pathways in Parkinson\u2019s disease. Neurochem. Res. 34, 55\u201365 (2009).","journal-title":"Neurochem. Res."},{"key":"83178_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.brainresbull.2019.05.020","volume":"152","author":"J-Q Liu","year":"2019","unstructured":"Liu, J.-Q., Chu, S.-F., Zhou, X., Zhang, D.-Y. & Chen, N.-H. Role of chemokines in Parkinson\u2019s disease. Brain Res. Bull. 152, 11\u201318 (2019).","journal-title":"Brain Res. Bull."},{"key":"83178_CR22","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3233\/JPD-202464","volume":"11","author":"E Camerucci","year":"2021","unstructured":"Camerucci, E. et al. Early-onset Parkinsonism and early-onset Parkinson\u2019s disease: A population-based study (2010\u20132015). J. Parkinson\u2019s Dis. 11, 1197\u20131207 (2021).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"83178_CR23","first-page":"51","volume":"3","author":"CA DeMarshall","year":"2016","unstructured":"DeMarshall, C. A. et al. Detection of Alzheimer\u2019s disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement. 3, 51\u201362 (2016).","journal-title":"Alzheimers Dement."},{"key":"83178_CR24","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox, C. et al. DrugBank 6.0: The DrugBank knowledgebase for 2024. Nucleic Acids Res. 52, 1265\u20131275 (2024).","journal-title":"Nucleic Acids Res."},{"key":"83178_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, 1\u201313 (2015).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83178-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T07:10:06Z","timestamp":1743059406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83178-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["83178"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83178-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5018761\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10563"}}